YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients (original) (raw)
Figure 3
YAP enhances chemotherapeutic drug resistance by ovarian cancer cells.
A: Viability of YAP-5SA and YAP-5SA-ΔC expressing cells after treatment with Taxol or CDDP, as assessed by MTT assay. B: Western blotting results for the apoptosis markers cleaved caspase 3 and PARP in YAP-5SA expressing and control cells after treatment with the indicated doses of CDDP for 48 h. C: Flow cytometry results for apoptosis of A2780CP cells with or without YAP-5SA-ΔC transfection and after treatment with different doses of CDDP for 48 h. D: Western blotting results for cleaved caspase 3 and PARP in YAP-5SA-ΔC expressing and control cells after treatment with the indicated doses of CDDP for 48 h. F-G: Images and quantitative results for in vivo tumorigenic capacity of A2780CP cells with or without YAP-5SA-ΔC expression. Nude mice were injected with CDDP through a caudal vein once each week for four weeks after tumor xenografts reached 5 mm in diameter. H: IHC results for the proliferation marker Ki67 on the indicated tumor tissue sections. Scale bar = 100 μM.